National Institute for Mediacal Research
Mwanza, Kagera, Tanzania
NCT Number: NCT02162875
The objective of this study is to determine the strategy for mass drug administration (MDA) which provides the greatest reductions in prevalence and intensity of Schistosoma mansoni in school-aged children after 4 years of intervention.
Looking for future studies?
Notify Me7 year–55 year
All sexes
Interventional
Not applicable
Mwanza, Kagera, Tanzania
Intestinal schistosomiasis is caused by the blood-dwelling flatworm Schistosoma mansoni. Despite the increasing focus on the use of praziquantel against schistosomiasis infections for the last three decades many areas in Sub-Saharan Africa still have high prevalences and intensities of schistosomiasis especially among school-age children. This is true for the area of Mwanza Region of Tanzania adjacent to Lake Victoria. The study is a six arm study and includes 150 communities (25 in each arm). From each community 100 school children (aged 9-12 years), 100 first year students (aged 7-8 years) and 50 adults (aged 20-55 years) are included, diagnosed and treated with praziquantel using strategies composing of a mixture of community wide treatment (CWT), school-based treatment (SBT) and years without treatment (-T). The 100 school children provided stool specimens on three consecutive days, while the 100 first year students and 50 adults with few exceptions only provided one specimen. The treatment strategies during the 4 years for the different arms are as follows: Arm 1: CWT, CWT, CWT, CWT; Arm 2: CWT, CWT, SBT, SBT; Arm 3: CWT, CWT -T, -T; Arm 4: SBT, SBT, SBT, SBT; Arm 5: SBT, SBT, -T, -T; Arm 6: SBT, -T, SBT, -T.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-All school children and adults who consent to participate can be included
Exclusion criteria
-Those not consenting or with any chronic disease not related to schistosomiasis will be excluded
Six different treatment strategies with praziquantel
Other names: no other drugs
Time frame: May -October 2016 (5 months)
Prevalence and intensity of Schistosoma mansoni
Time frame: May -October 2016 (5 months)
Coverage of treatment
Time frame: May-October 2016 (5 months)
Cost of different treatment arm
DBL -Institute for Health Research and Development
Other
Parasitologic Impact of Different Mass Drug Administration Strategies Against Schistosoma Mansoni in Endemic Areas of Mwanza Region, Tanzania, Where Prevalence is 25% or Above
Acronym: SCORE_PAR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03910972
Helminthiasis, Infections
Kampala, Uganda
View Trial DetailsNCT05085470
Helminthiasis, Infections
Leiden, Netherlands
View Trial DetailsNCT04679831
Helminthiasis, Infections
Mbita, Kenya
View Trial DetailsNCT03893097
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Dakar, Senegal
View Trial Details